Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 215.6 SEK 3.65%
Market Cap: 29.2B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Vitrolife AB
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vitrolife AB
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Vitrolife AB
STO:VITR
PP&E Net
kr391m
CAGR 3-Years
35%
CAGR 5-Years
17%
CAGR 10-Years
16%
Biogaia AB
STO:BIOG B
PP&E Net
kr213.3m
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
PP&E Net
kr20.6m
CAGR 3-Years
11%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Probi AB
STO:PROB
PP&E Net
kr237.8m
CAGR 3-Years
22%
CAGR 5-Years
20%
CAGR 10-Years
61%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
PP&E Net
kr384m
CAGR 3-Years
-7%
CAGR 5-Years
-5%
CAGR 10-Years
13%
BioArctic AB
STO:BIOA B
PP&E Net
kr31.1m
CAGR 3-Years
-8%
CAGR 5-Years
27%
CAGR 10-Years
N/A
No Stocks Found

Vitrolife AB
Glance View

Market Cap
29.2B SEK
Industry
Biotechnology

Vitrolife AB is a Swedish company that has carved out a significant niche within the biotechnology sector, particularly within reproductive health. Founded in 1994, Vitrolife focuses on the development, production, and commercialization of products designed to optimize fertility treatments. The company’s offerings include a wide range of medical devices and culture media critical for in vitro fertilization (IVF) procedures. These products are used by fertility clinics across the globe, enhancing every stage of assisted reproduction — from egg retrieval and sperm preparation to embryo transfer. This comprehensive approach not only amplifies treatment outcomes but also strengthens Vitrolife's position as a pivotal player in a market where scientific advancement and patient care converge. The company’s business model thrives on a robust combination of research-driven innovation and strategic acquisitions. By continuously refining its product lines and leveraging strategic partnerships with clinics and research institutes, Vitrolife ensures that it remains at the cutting edge of the rapidly evolving fertility landscape. Revenue streams flow in through the sales of these critical fertility products, supported by a well-established distribution network that bridges its Swedish roots with a global customer base. With a commitment to quality and efficacy, Vitrolife makes money by delivering solutions that enhance the success rates of fertility treatments, making the dream of parenthood possible for many around the world.

VITR Intrinsic Value
136.75 SEK
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Vitrolife AB's PP&E Net?
PP&E Net
391m SEK

Based on the financial report for Sep 30, 2024, Vitrolife AB's PP&E Net amounts to 391m SEK.

What is Vitrolife AB's PP&E Net growth rate?
PP&E Net CAGR 10Y
16%

Over the last year, the PP&E Net growth was 11%. The average annual PP&E Net growth rates for Vitrolife AB have been 35% over the past three years , 17% over the past five years , and 16% over the past ten years .

Back to Top